Objective:To evaluate the efficacy of paclitaxel-coated balloon(PCB)in the treatment of extra-long femoropopliteal artery atherosclerotic disease(>30 cm).Materials and methods:Forty-nine patients with extra-long fe...Objective:To evaluate the efficacy of paclitaxel-coated balloon(PCB)in the treatment of extra-long femoropopliteal artery atherosclerotic disease(>30 cm).Materials and methods:Forty-nine patients with extra-long femoropopliteal artery atherosclerotic disease were treated with PCB alone in a single center from July 2016 to May 2018.Primary patency and freedom from clinically driven target lesion revascularization(FF-CDTLR)rates during 12 months were analyzed retrospectively.Results:All patients were followed up for 18.2±7.5 months,and the mean treated lesion length was 34.9±3.7 cm.The primary patency rates were 87.8%(43/49)and 71.4%(35/49)at 6 and 12 months,respectively.FFCDTLR was 91.8%(45/49)and 77.6%(38/49)at 6 and 12 months,respectively.No mortality or amputation occurred in these patients during the follow-up period.Conclusions:PCB has favorable clinical efficacy in patients with extra-long femoropopliteal artery atherosclerotic lesions.展开更多
Background：Sarpogrelate is a selective 5-hydroxytryptamine （5-HT） receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells.We compared the effi...Background：Sarpogrelate is a selective 5-hydroxytryptamine （5-HT） receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells.We compared the efficacy of sarpogrelate-based dual antiplatelet therapies for the prevention of restenosis and target lesion revascularization （TLR） rates comparing with that of clopidogrel after percutaneous endovascular interventions （EVIs） of femoropopliteal （FP） arterial lesions.Methods：This prospective,multicenter,randomized clinical trial recruited a total of 120 patients with successful EVI of FP lesions at seven centers across China between January 2011 and June 2012.Patients were randomized to receive either sarpogrelate （100 mg trice daily for 6 months,n =63） or clopidogrel （75 mg once daily for 6 months,n =57）.All patients also received oral aspirin （100 mg once daily for 12 months）.Clinical follow-up was conducted up to 12 months postprocedure.Results：There was no significant difference between the two groups in basic demographic data.The restenosis rate was higher in the clopidogrel group （22.80%） than in sarpogrelate group （17.50%）,but there was no significant difference between these two groups （P =0.465）.The TLR rate,ipsilateral amputation rate,mortality in all-cause and bleeding rate were also similar in the two groups （P 〉 0.05）.Conclusions：Aspirin plus sarpogrelate is a comparable antithrombotic regimen to aspirin plus clopidogrel after EVI of FP arterial lesions.Dual antiplatelet therapies might play an important role in preventing restenosis after successful EVI of FP lesions.展开更多
文摘Objective:To evaluate the efficacy of paclitaxel-coated balloon(PCB)in the treatment of extra-long femoropopliteal artery atherosclerotic disease(>30 cm).Materials and methods:Forty-nine patients with extra-long femoropopliteal artery atherosclerotic disease were treated with PCB alone in a single center from July 2016 to May 2018.Primary patency and freedom from clinically driven target lesion revascularization(FF-CDTLR)rates during 12 months were analyzed retrospectively.Results:All patients were followed up for 18.2±7.5 months,and the mean treated lesion length was 34.9±3.7 cm.The primary patency rates were 87.8%(43/49)and 71.4%(35/49)at 6 and 12 months,respectively.FFCDTLR was 91.8%(45/49)and 77.6%(38/49)at 6 and 12 months,respectively.No mortality or amputation occurred in these patients during the follow-up period.Conclusions:PCB has favorable clinical efficacy in patients with extra-long femoropopliteal artery atherosclerotic lesions.
文摘Background：Sarpogrelate is a selective 5-hydroxytryptamine （5-HT） receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells.We compared the efficacy of sarpogrelate-based dual antiplatelet therapies for the prevention of restenosis and target lesion revascularization （TLR） rates comparing with that of clopidogrel after percutaneous endovascular interventions （EVIs） of femoropopliteal （FP） arterial lesions.Methods：This prospective,multicenter,randomized clinical trial recruited a total of 120 patients with successful EVI of FP lesions at seven centers across China between January 2011 and June 2012.Patients were randomized to receive either sarpogrelate （100 mg trice daily for 6 months,n =63） or clopidogrel （75 mg once daily for 6 months,n =57）.All patients also received oral aspirin （100 mg once daily for 12 months）.Clinical follow-up was conducted up to 12 months postprocedure.Results：There was no significant difference between the two groups in basic demographic data.The restenosis rate was higher in the clopidogrel group （22.80%） than in sarpogrelate group （17.50%）,but there was no significant difference between these two groups （P =0.465）.The TLR rate,ipsilateral amputation rate,mortality in all-cause and bleeding rate were also similar in the two groups （P 〉 0.05）.Conclusions：Aspirin plus sarpogrelate is a comparable antithrombotic regimen to aspirin plus clopidogrel after EVI of FP arterial lesions.Dual antiplatelet therapies might play an important role in preventing restenosis after successful EVI of FP lesions.
